Ireland Lucy V, Mielgo Ainhoa
Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
Front Cell Dev Biol. 2018 Oct 9;6:131. doi: 10.3389/fcell.2018.00131. eCollection 2018.
Chemotherapy is routinely used in cancer treatment to eliminate primary and metastatic tumor cells. However, tumors often display or develop resistance to chemotherapy. Mechanisms of chemoresistance can be either tumor cell autonomous or mediated by the tumor surrounding non-malignant cells, also known as stromal cells, which include fibroblasts, immune cells, and cells from the vasculature. Therapies targeting cancer cells have shown limited effectiveness in tumors characterized by a rich tumor stroma. Tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) are the most abundant non-cancerous cells in the tumor stroma and have emerged as key players in cancer progression, metastasis and resistance to therapies. This review describes the recent advances in our understanding of how CAFs and TAMs confer chemoresistance to tumor cells and discusses the therapeutic opportunities of combining anti-tumor with anti-stromal therapies. The continued elucidation of the mechanisms by which TAMs and CAFs mediate resistance to therapies will allow the development of improved combination treatments for cancer patients.
化疗在癌症治疗中被常规用于消除原发性和转移性肿瘤细胞。然而,肿瘤常常表现出或产生对化疗的抗性。化疗抗性机制可以是肿瘤细胞自主性的,也可以由肿瘤周围的非恶性细胞介导,这些非恶性细胞也被称为基质细胞,包括成纤维细胞、免疫细胞和血管细胞。在以丰富的肿瘤基质为特征的肿瘤中,针对癌细胞的疗法已显示出有限的有效性。肿瘤相关巨噬细胞(TAM)和癌症相关成纤维细胞(CAF)是肿瘤基质中最丰富的非癌细胞,并已成为癌症进展、转移和治疗抗性的关键参与者。本综述描述了我们对CAF和TAM如何赋予肿瘤细胞化疗抗性的理解的最新进展,并讨论了将抗肿瘤与抗基质疗法相结合的治疗机会。对TAM和CAF介导治疗抗性的机制的持续阐明将有助于为癌症患者开发改进的联合治疗方法。